Table 2.
Characteristics of 207 Cirrhotic Patients Infected with HCV Included in the Analysis.
| Parameter | Patients with Liver Cirrhosis, n = 207 |
|---|---|
| Gender, females/males, n (%) | 97 (46.9)/110 (53.1) |
| Age [years] mean ± SD; min.–max. | 59 ± 13.7; 21–89 |
| Median (Q1, Q3) | 60.0 (50.5, 69.0) |
| Females, age [years] mean ± SD; min.–max. | 62.4 ± 12.7; 21–89 |
| Median (Q1, Q3) | 63.0 (56.0, 71.0) |
| Males, age [years] mean ± SD; min.–max. | 56 ± 13.9; 21–89 |
| Median (Q1, Q3) | 57.0 (46.0, 65.8) |
| BMI [kg/m2] mean ± SD; min.–max. | 27 ± 5.1; 17.5–44.9 |
| Median (Q1, Q3) | 26.6 (23.6, 29.7) |
| GT, n (%) | |
| 1 | 2 (1) |
| 1a | 1 (0.5) |
| 1b | 169 (81.6) |
| 2 | 0 |
| 3 | 32 (15.4) |
| 4 | 2 (1) |
| 5 | 0 |
| 6 | 1 (0.5) |
| Comorbidities, n (%) | |
| Any comorbidity | 197 (95.2) |
| Hypertension | 102 (49.3) |
| Diabetes | 53 (25.6) |
| Renal disease | 23 (11.1) |
| Autoimmune diseases | 11 (5.3) |
| Non-HCC tumors | 11 (5.3) |
| Other | 185 (89.4) |
| Concomitant medications, n (%) | 188 (90.8) |
| Diuretics, n (%) | 92 (44.4) |
| History of hepatic decompensation, n (%) | |
| Ascites | 28 (13.5) |
| Encephalopathy | 11 (5.3) |
| Documented esophageal varices, n (%) | 89 (43) |
| Hepatic decompensation at baseline, n (%) | |
| Moderate ascites–responded to diuretics | 20 (9.7) |
| Tense ascites–not responded to diuretics | 4 (1.9) |
| Encephalopathy | 6 (2.9) |
| HCC history, n (%) | 8 (3.9) |
| OLTx history, n (%) | 0 |
| Child-Pugh, n (%) | |
| A | 171 (82.6) |
| B | 31 (15) |
| C | 5 (2.4) |
| MELD, n (%) | |
| <15 | 189 (91.3) |
| 15–18 | 17 (8.2) |
| 19–20 | 0 |
| >20 | 1 (0.5) |
| HBV coinfection (HBsAg+), n (%) | 3 (1.4) |
| HIV coinfection, n (%) | 0 |
| Extrahepatic manifestations of HCV, n (%) | |
| Cryoglobulinemia | 132 (63.8) |
| Thyroid abnormalities with the presence of anti-thyroid antibodies | 18 (8.7) |
| Other | 2 (1) |
| History of previous therapy, n (%) | |
| Treatment-naive | 133 (64.2) |
| Non-responder | 37 (17.9) |
| Relapser | 24 (11.6) |
| Discontinuation due to safety reason | 13 (6.3) |
| Treatment regimens, n (%) | |
| ASV + DCV | 5 (2.4) |
| LDV/SOF ± RBV | 56 (27.1) |
| OBV/PTV/r ± DSV ± RBV | 51 (24.6) |
| GZR/EBR | 22 (10.6) |
| SOF + SMV ± RBV | 4 (1.9) |
| SOF + RBV | 18 (8.7) |
| SOF + DCV + RBV | 1 (0.5) |
| GLE/PIB | 21 (10.2) |
| SOF/VEL ± RBV | 29 (14) |
| ALT IU/L, mean ± SD | 97.2 ± 68.3 |
| Median (Q1, Q3) | 78.0 (48.5, 127.0) |
| Bilirubin mg/dL, mean ± SD | 1.5 ± 1.8 |
| Median (Q1, Q3) | 1.2 (0.9, 1.7) |
| Albumin g/dL, mean ± SD | 3.6 ± 0.5 |
| Median (Q1, Q3) | 3.6 (3.3, 3.9) |
| Creatinine mg/dL, mean ± SD | 0.9 ± 0.3 |
| Median (Q1, Q3) | 0.9 (0.8, 1.0) |
| Hemoglobin g/dL, mean ± SD | 13.6 ± 1.7 |
| Median (Q1, Q3) | 13.8 (12.4, 14.6) |
| Platelets, ×1000/µL, mean ± SD | 108.7 ± 57.4 |
| Median (Q1, Q3) | 97.0 (71.0, 136.5) |
| HCV RNA × 106 IU/mL, mean ± SD | 1.9 ± 5.2 |
| Median (Q1, Q3) | 0.5 (0.1, 1.5) |
ALT: alanine transaminase; ASV: asunaprevir; BMI: body mass index; DCV: daclatasvir; DSV: dasabuvir; EBR: elbasvir; GLE: glecaprevir; GT: genotype; GZR: grazoprevir; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HCV RNA: ribonucleic acid of hepatitis C virus; HIV: human immunodeficiency virus; LDV: ledipasvir; MELD: Model End-Stage Liver Disease; OBV: ombitasvir; OLTx: orthotopic liver transplantation; PIB: pibrentasvir; PTV/r: paritaprevir; RBV: ribavirin; SD: standard deviation; SMV: simeprevir; SOF: sofosbuvir; VEL: velpatasvir.